History Repeats: Will US Stelara Settlements Follow Humira’s Lead?
Adalimumab Example Could Provide A Playbook For Settlements Over Ustekinumab Biosimilars
Executive Summary
Hopes are rising that Johnson & Johnson will be able to emulate AbbVie’s success in delaying US biosimilar competition to its top-selling Humira by using a similar settlement strategy with its anti-IL12/IL23 blockbuster Stelara.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Lilly’s latest acquisition; the outlook for Stelara biosimilars; better biomarkers needed in the TIGIT/PD-1 combo field?; Sanofi on the deal-making landscape; and the shifting KRAS race in China.
All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch
The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.
Indian Leaders Climb Into Generics And Biosimilars Top 10
In a year that has seen significant changes throughout the generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders. Meanwhile, companies lower down our ranking have enjoyed mixed fortunes, leading to a number of significant movements in this year’s Generics Bulletin Top 50.